Börsenbriefempfehlung mit Kurspotential 100 % ...

Seite 1 von 2
neuester Beitrag: 10.12.19 20:38
eröffnet am: 12.03.15 19:15 von: MarcEffi Anzahl Beiträge: 37
neuester Beitrag: 10.12.19 20:38 von: Balu4u Leser gesamt: 15605
davon Heute: 4
bewertet mit 2 Sternen

Seite: 1 | 2  

12.03.15 19:15

18 Postings, 3521 Tage MarcEffiBörsenbriefempfehlung mit Kurspotential 100 % ...

Es gibt eine massive Börsenbriefempfehlung mit Kurspotential 100 % auf Sicht von 4 Monate.

Die Empfehlung ist von Anfang März 2015.

Was haltet ihr von dem Wert? Einstieg auf kurzer Sicht lohnenswert oder nur ein Push-Versuch?

Seite: 1 | 2  
11 Postings ausgeblendet.

18.10.16 20:33

4140 Postings, 3287 Tage chinaskyPlan to sale options between Dez.16 and Jan.17

Date 07.10.2016

Zitat:"Mr Gover's plan provides for the exercise and sale of options over up to 372,823 Ordinary 0.1p Shares (equivalent to 31,068 American Depository Shares), between 9 December 2016 and 1 April 2017 in order to avoid otherwise adverse personal taxation implications of non-exercise of these options........Following exercise of these options, Mr Gover will continue to hold 1,057,293 options over Ordinary Shares (equivalent to 88,107 ADSs) and will continue to be the beneficial owner of an additional 2,513,759 Ordinary Shares (equivalent to 209,479 ADSs).  " ENDE Zitat

21.02.17 15:33

4140 Postings, 3287 Tage chinaskythey want to be the only option....

Zitat:"....The proposed measures would effectively give GW/Greenwich a temporary monopoly on legal CBD products ... " ENDE Zitat



28.04.17 10:55

4140 Postings, 3287 Tage chinaskyGWPH´s Pharm.Develepment Pipeline

Angehängte Grafik:
gwph_pipeline.jpg (verkleinert auf 84%) vergrößern

25.05.17 15:35

4140 Postings, 3287 Tage chinaskyEpidiolex significantly reduced seizure frequency

Zitat:".. formulation of cannabidiol significantly reduced convulsive seizure frequency in children on multiple anti-epileptic drugs with poor seizure control ? Lead study author and director of the Comprehensive Epilepsy Center at NYU Langone Medical Center ;CEO, GW Pharmaceuticals/Greenwich Biosciences...? First well-controlled clinical study of cannabidiol in Dravet syndrome, a rare, severe type of epilepsy with no FDA-approved treatments ? " ENDE Zitat


09.11.17 19:11

78 Postings, 1435 Tage SakulaJemand

schon mal bei Veritas Pharma vorbeigeschaut?
Ähnliches Geschäftsmodell wie GW nur sehr neu und daher ist die Aktie gefühlt extrem unterbewertet. Macht einen guten Eindruck, zumindest vom Webauftritt und zu findenden Infos.  

22.12.17 08:11

245 Postings, 829 Tage MedicalSativex - GW has now full ownership

Zitat:"GW Pharmaceuticals plc (Nasdaq:GWPH) (?GW? or ?the Company?), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announces the termination of its previous license agreement with Otsuka Pharmaceutical Co., Ltd. in relation to Sativex® (nabiximols) in the U.S. As a result, GW has now reacquired full ownership of the development and commercialization rights to the product in the U.S. market without making any upfront payment to Otsuka. ...." ENDE Zitat


Fazit: .. (rein subjektiv - keine Aufforderung zu jegwelchem Handeln...) wer jedoch an Sativex und der medizinischen Grundlage von Cannabinoiden und den daraus resultierenden Chancen für GW Pharmaceuticals glaubt, kann sich bei Interesse ggf. mal mein Wiki ansehen,...
mit 46% Gesamtgewichtung bei GW Pharmaceuticals ADR? ist dieses jedoch als hochspekulativ zu werten!  
Cannabinoide sind künftig unter Umständen eine alternative Möglichkeit, bei der Reduzierung von Spasmen, sowie der Linderung und medizinischen Unterstützung bei Multiple Sklerose. Das "Cannabis & Cannabinoids Industryr" Wikifolio, soll am künftigen Erfolg von Sativex und einem Wertzuwachs des Unternehmens versuchen zu partizipieren....

Kurs 112,509 Stk.3.000 (Wert 337.527,000) +6.935,950 +2,10 %  aktuelle Gewichtung 46,5 %  

03.01.18 16:50

245 Postings, 829 Tage MedicalGWPH submitted MarketingAuthorisationApp EMA

Zitat:" announced it has submitted its Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Epidiolex® (cannabidiol or CBD) as adjunctive treatment for seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome, two highly treatment-resistant forms of childhood-onset epilepsy.  GW has received Orphan Designations from the EMA for Epidiolex for the treatment of LGS, Dravet syndrome, and recently, West syndrome and Tuberous Sclerosis Complex. In October 2017, GW completed the submission of its rolling Epidiolex New Drug Application (NDA) to the United States Food and Drug Administration (FDA), also for seizures associated with LGS and Dravet syndrome. This NDA has been accepted by the FDA for Priority Review....."This MAA submission marks another major milestone for the Epidiolex program and is an important next step toward providing this potential new treatment option globally," stated Justin Gover, CEO of GW Pharmaceuticals...." ENDE Zitat

15.03.18 19:41

245 Postings, 829 Tage Medical5 new Epidiolex Patents - expire in 2035

Zitat:"...GW Pharmaceuticals Announces Receipt of Notices of Allowance by the United States Patent and Trademark Office (USPTO) for Five New Epidiolex ® (cannabidiol) Patents...... Calif., March 13, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (?GW,? ?the Company? or ?the Group?), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, today announced receipt of Notices of Allowance for five new Epidiolex® patent applications that will be listed in the Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book) if the NDA for Epidiolex is approved. Once issued, these patents are set to expire in 2035. One or more patents may be eligible for additional patent term through patent term adjustment and/or regulatory excl...?The allowance of these important patent applications confirms GW?s innovative science and........... leadership in developing cannabinoid-based medicines and provides meaningful additional exclusivity for Epidiolex,? stated Justin Gover, GW?s Chief Executive Officer. ?We have numerous additional patent applications ....................under prosecution at the USPTO and will continue to work to expand our patent portfolio as we innovate and develop new Epidiolex formulations and additional products......? ENDE Zitat


23.04.18 12:47

245 Postings, 829 Tage MedicalGreenwich Bios. Announces iResult of FDA

Zitat:".... its U.S. subsidiary Greenwich Biosciences, today announced that the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) unanimously recommended supporting the approval of the New Drug Application (NDA) for the investigational cannabidiol oral solution (CBD), also known as Epidiolex®, for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome in patients two years of age and older. If approved, Epidiolex would be the first pharmaceutical formulation of purified, plant-based CBD, a cannabinoid lacking the high associated with marijuana, and the first in a new category of anti-epileptic drugs (AEDs)...." ENDE Zitat

23.08.18 15:53

245 Postings, 829 Tage MedicalOperational & Financial Highlights 3-Q.2018


   Epidiolex (cannabidiol)
           FDA approval for the treatment of seizures associated with LGS or Dravet syndrome
           Epidiolex rescheduling expected within 90 days of FDA approval
           European submission under review by the EMA with decision expected in Q1 2019
           FDA issuance of a priority review voucher (PRV) for Epidiolex.
           Commercial product being manufactured and prepared for shipping to the U.S.
           Continued investment in expanded facilities to meet anticipated long-term demand  
           U.S. sales organization fully recruited comprising two national directors, eight regional managers plus 66 Neurology Account Managers  
           Active engagement with U.S. payors ongoing with clinical presentations to plans that cover over 80% of covered lives in the U.S.
           U.S. supply chain platform in place which will employ a closed model distribution network of five Specialty Pharmacy Providers (SPP?s)
           Commercial footprint in place in 5 major European markets in readiness for 2019 European launches
       Epilepsy Clinical trials
           Three Phase 3 clinical trials published - two in The New England Journal of Medicine and one in The Lancet
           Phase 3 trial in Tuberous Sclerosis Complex ongoing with data expected H1 2019
           Decision to expand target indications for Epidiolex beyond epilepsy to autism. IND expected to be submitted for pivotal Rett Syndrome study in Q4 18.
       Expanded access program and open label extension:
           Over 2,000 patients now have been exposed to Epidiolex treatment
       Life-cycle management
           Several new formulations of CBD in development including modified oral solution, capsule and an intravenous formulation
           7-year orphan exclusivity confirmed by FDA, 6-month pediatric extension expected
           Key favorable patent grants by USPTO related to the use of CBD in epilepsy, including claims for the treatment of relevant seizure types associated with LGS and Dravet syndrome, as well as the use of CBD with clobazam
               Patents align directly with new Epidiolex FDA label and to be listed in Orange Book
               Patent expiry dates to 2035
           Additional patent applications under review and being filed as new data is generated
   Pipeline progress
       Sativex® (nabiximols)
           U.S. development and commercialization rights wholly owned by GW
           Initial U.S. target indication: Multiple Sclerosis spasticity. Three positive Phase 3 trials completed in Europe
           Plans to meet with FDA in H2 18 to determine MS spasticity regulatory pathway in the U.S.
           Over 20 placebo-controlled trials already completed in other indications, representing significant U.S. lifecycle management opportunities
           10-patient investigator-initiated expanded access program for seizures associated with autism underway
           Investigator-led 100 patient placebo-controlled trial in autism spectrum disorder due to commence in Q3 18
           Open label study in Rett syndrome and seizures due to commence Q3 18
       CBD:THC in Glioblastoma
           Recent data presented from the Phase 2 study showed significant increase in median survival for patients taking CBD:THC of 662 days compared to 369 days on placebo
           Pivotal clinical development program plans under development
           Orphan Drug Designation from both FDA and EMA for CBD:THC to treat glioblastoma
       Neonatal Hypoxic-Ischemic Encephalopathy (NHIE) intravenous CBD program
           Phase 1 trial complete
           Orphan Drug and Fast Track Designations granted from FDA and EMA
           Phase 2 trial in planning


   Cash and cash equivalents at 30 June 2018 of £334.0 million ($440.2 million) compared to £241.2 million as at 30 September 2017
   Revenue for the nine months ended 30 June 2018 of £10.7 million ($14.2 million) compared to £6.1 million for the nine months ended 30 June 2017
   Loss for the nine months ended 30 June 2018 of £136.7 million ($180.2 million) compared to £90.3 million for the nine months ended 30 June 2017... " ENDE ZItat


20.09.18 07:39

245 Postings, 829 Tage MedicalDEA down-calssify GW Pharma´s Epidiolex ??

Zitat:"U.S. DEA to down-classify GW Pharma's Epidiolex; .....Sep. 19, 2018 1:04 PM ET|About: GW Pharmaceuticals plc (GWPH)|By: Douglas W. House, SA News Editor...GW Pharmaceuticals (GWPH +8%) is up on more than a 4x surge in volume on the heels of a report by Morgan Stanley's David Lebowitz (OVERWEIGHT/$197) saying the U.S. Drug Enforcement Administration (DEA) is expected to reclassify Epidiolex (cannabidiol) to allow for medicinal use....The medication, approved by the FDA about two months ago for severe forms of epilepsy, is currently categorized as Schedule I alongside heroin and cocaine.The revised classification, expected to occur in the next few days, will move Epidiolex to Schedule IV, the same class as Xanax, Ambien and Tramadol... "ENDE Zitat

20.09.18 07:46

245 Postings, 829 Tage Medical5Jahres-Chart GWPH

Angehängte Grafik:
gwph_5y_2013-2018.jpg (verkleinert auf 61%) vergrößern

27.09.18 19:10

245 Postings, 829 Tage MedicalEpidiolex transferred to Schedule V. by DEA

Zitat:"LONDON and CARLSBAD, Calif., Sept. 27, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, ?GW,? ?the Company? or ?the Group?), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that EPIDIOLEX® (cannabidiol) oral solution has been transferred to Schedule V, the lowest restriction classification, by the U.S. Drug Enforcement Administration (DEA). EPIDIOLEX, which was approved by the U.S. Food and Drug Administration (FDA) on June 25, 2018 for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older, is the first prescription pharmaceutical formulation of highly-purified, plant-derived cannabidiol (CBD), a cannabinoid lacking the high associated with marijuana, and the first in a new category of anti-epileptic drugs (AEDs)...." ENDE Zitat

27.09.18 20:52

1688 Postings, 668 Tage neymarGw Pharma

DEA permits GW Pharma to sell cannabis derived drug, CEO says there is...

20.11.18 11:08

245 Postings, 829 Tage MedicalResults of completed Phase 3 Trials Epidiolex

Zitat:"GW Pharmaceuticals plc (Nasdaq: GWPH, ?GW,? ?the Company? or ?the Group?), the world leader in the development and commercialization of cannabinoid prescription medicines, along with its U.S. subsidiary Greenwich Biosciences, announced today that results from completed Phase 3 trials of EPIDIOLEX® (cannabidiol) oral solution CV, as well as new pre-clinical and Phase 1 cannabinoid research, will be presented at the American Epilepsy Society (AES) Annual Meeting, November 30-December 4, 2018, in New Orleans, Louisiana. EPIDIOLEX is FDA-approved and available by prescription in the U.S. for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age and older...." ENDE Zitat

20.11.18 11:11

245 Postings, 829 Tage MedicalSafety Information & Indications in EPIDIOLEX

Important Safety Information & Indications
What is the Most Important Information I Should Know About EPIDIOLEX?
Do not take if you are allergic to cannabidiol or any of the ingredients in EPIDIOLEX.
EPIDIOLEX may cause liver problems. Your doctor may order blood tests to check your liver before you start taking EPIDIOLEX and during treatment. In some cases, EPIDIOLEX treatment may need to be stopped. Call your doctor right away if you start to have any of these signs and symptoms of liver problems during treatment with EPIDIOLEX:

   loss of appetite, nausea, vomiting
   fever, feeling unwell, unusual tiredness
   yellowing of the skin or the whites of the eyes (jaundice)
   unusual darkening of the urine
   right upper stomach area pain or discomfort

EPIDIOLEX may cause you to feel sleepy, which may get better over time. Other medicines (e.g., clobazam) or alcohol may increase sleepiness. Do not drive, operate heavy machinery, or do other dangerous activities until you know how EPIDIOLEX affects you.

Like other antiepileptic drugs, EPIDIOLEX may cause suicidal thoughts or actions in a very small number of people, about 1 in 500.


20.11.18 11:15

245 Postings, 829 Tage Medical5-Y Chart GWPH

Angehängte Grafik:
gwph-5y-chart-20112018.jpg (verkleinert auf 61%) vergrößern

07.05.19 13:36

245 Postings, 829 Tage Medicalpositive top-line results Phase 3 clinical trial

Zitat:"CARLSBAD, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced positive top-line results of a randomized, double-blind, placebo-controlled Phase 3 clinical trial of EPIDIOLEX® (cannabidiol or CBD) CV in the treatment of seizures associated with Tuberous Sclerosis Complex (TSC), a rare and severe form of childhood-onset epilepsy. In this trial, EPIDIOLEX met its primary endpoint, which was the reduction in seizure frequency compared to baseline of the Epidiolex 25 mg/kg/day dose group vs placebo (p=0.0009).  Results for both the 25 and 50 mg/kg/day dose groups were similar, with seizure reductions of 48.6% and 47.5% from baseline respectively, vs 26.5% for placebo (50 mg/kg/day vs placebo, p=0.0018). All key secondary endpoints were supportive of the effects on the primary endpoint. The safety profile observed is consistent with findings from previous studies, with no new safety risks identified.......?The positive outcome in this trial of EPIDIOLEX in patients with Tuberous Sclerosis Complex expands both our knowledge of this newly available medicine and its potential utility beyond the current indications,?...ENDE Zitat

08.05.19 08:07

245 Postings, 829 Tage Medical5-Y Chart GWPH

Angehängte Grafik:
gwph-5y-chart-07052019.jpg (verkleinert auf 58%) vergrößern

19.10.19 08:50

245 Postings, 829 Tage Medical5-Y Chart GWPH

Angehängte Grafik:
gwph-5y-chart-18102019.jpg (verkleinert auf 58%) vergrößern

21.10.19 18:49

14 Postings, 1164 Tage AthenisGrüezi Medical

Hat jemand in diesem Thread Musse oder vielleicht im Tagesgeschäft genug Langeweile um mir zu erklären was das Chart zu bedeuten hat? Ich bin Anfängerin und charts sind für mich noch sehr schwer zu verstehen. obwohl ich nichts verstehe bin ich investiert.
Lieben Dank im Voraus  

21.11.19 15:46

245 Postings, 829 Tage MedicalGap-Close ?!

Angehängte Grafik:
gwph-1y-chart-18112019-1gap.jpg (verkleinert auf 57%) vergrößern

21.11.19 15:52

245 Postings, 829 Tage Medical..

..sorry für das Gekritzel

... im Nachfolgenden Link / Bericht , lässt sich das Gap im Oktober 2016 (aus meiner Sicht) gut erkennen.

....      : "Jedes Gap wird irgendwann einmal geschlossen..."  

Seite: 1 | 2  
   Antwort einfügen - nach oben

Online Brokerage über Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von!


Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Euro US-Dollar
Wirecard AG747206
Ballard Power Inc.A0RENB
Daimler AG710000
Deutsche Bank AG514000
Varta AGA0TGJ5
Apple Inc.865985
PowerCell Sweden ABA14TK6
Microsoft Corp.870747